Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCL8 | P10145 | 2/20 | 0.45 |
| ▸ | LMNA | P02545 | 3/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | RPS6KB1 | P23443 | 2/20 | 0.41 |
| ▸ | AURKA | O14965 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | SRC | P12931 | 1/20 | 0.41 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.41 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.41 |
| ▸ | AKR1B10 | O60218 | 1/20 | 0.41 |
| ▸ | UGT1A9 | O60656 | 1/20 | 0.41 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.41 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.41 |
| ▸ | MT-CO2 | P00403 | 1/20 | 0.41 |
| ▸ | TTR | P02766 | 1/20 | 0.41 |
| ▸ | ALB | P02768 | 1/20 | 0.41 |
| ▸ | UGT1A6 | P19224 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11271011 | 0.98 | CXCL8 (0.44) | CXCL8LMNAMEN1KMT2ACA1 | |
| SCHEMBL6809250 | 0.98 | CXCL8 (0.44) | CXCL8LMNAMEN1KMT2ACA1 | |
| SCHEMBL28355542 | 0.90 | FPR2 (0.42) | CXCL8LMNAMEN1KMT2ACA1 | |
| SCHEMBL5007635 | 0.89 | GAA (0.43) | CXCL8LMNAMEN1KMT2ACA1 | |
| SCHEMBL27562422 | 0.88 | MEN1 (0.41) | CXCL8LMNAMEN1KMT2APTGS1 | |
| Trolamine SCHEMBL10993885 | 0.87 | CXCL8 (0.37) | CXCL8LMNAMEN1KMT2ACA1 | |
| SCHEMBL7165977 | 0.87 | OPRK1 (0.44) | CXCL8LMNAMEN1KMT2ACA1 | |
| SCHEMBL7574221 | 0.86 | ALDH1A1 (0.44) | MEN1KMT2ACA1CA2CYP2D6 | |
| SCHEMBL9350140 | 0.85 | PTGS1 (0.46) | CXCL8LMNAMEN1KMT2APTGS1 | |
| SCHEMBL7573697 | 0.85 | CAMK2A (0.44) | LMNAMEN1KMT2ACA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 387 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12285487-B2 | Liquid topical pharmaceutical nano-emulsion formulations | JRX BIOTECHNOLOGY, INC. (US) | 2025-04-29 | — | — | US | claimed |
| US-20230017266-A1 | Cyclooxygenase-2 Inhibition for the Treatment of SAA-high Asthma | THE USA, AS REPRESENTED BY THE SECRETARY, DEPT. OF HEALTH AND HUMAN SERVICES (US) | 2023-01-19 | — | — | US | claimed |
| EP-4069213-A1 | CYCLOOXYGENASE-2 INHIBITION FOR THE TREATMENT OF SAA-HIGH ASTHMA | The USA, as represented by The Secretary, Department of Health and Human Services (US) | 2022-10-12 | — | — | EP | claimed |
| US-11389512-B2 | Use of low molecular weight fractions of human serum albumin in treating diseases | AMPIO PHARMACEUTICALS, INC, | 2022-07-19 | — | — | US | claimed |
| WO-2021113498-A1 | CYCLOOXYGENASE-2 INHIBITION FOR THE TREATMENT OF SAA-HIGH ASTHMA | THE USA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2021-06-10 | — | — | WO | claimed |
| CN-109207148-A | A kind of magnanimity preparation method of high yield carbon quantum dot | 张宏伟 | 2019-01-15 | — | — | CN | claimed |
| US-20180169067-A1 | COMBINATION DRUG THERAPIES FOR CANCER AND METHODS OF MAKING AND USING THEM | VICUS THERAPEUTICS LLC (US) | 2018-06-21 | — | — | US | claimed |
| EP-3310375-A1 | USE OF LOW MOLECULAR WEIGHT FRACTIONS OF HUMAN SERUM ALBUMIN IN TREATING DISEASES | Ampio Pharmaceuticals, Inc. (US) | 2018-04-25 | — | — | EP | claimed |
| CN-104173321-B | The method for preparing pharmaceutical composition being administered by external use plaster, with anti-inflammatory analgesic activity, and the composition obtained with this | 阿尔特根有限公司 | 2017-10-31 | — | — | CN | claimed |
| US-20170202806-A1 | COMBINATION DRUG THERAPIES FOR CANCER AND METHODS OF MAKING AND USING THEM | VICUS THERAPEUTICS LLC (US) | 2017-07-20 | — | — | US | claimed |
| WO-2003013499-A2 | DRUGS FOR VASCULOPATIES | NICOX S.A. (FR) | 2003-02-20 | — | — | WO | claimed |
| EP-0498011-B1 | Salts of the 2-(2,6-dichloroanilino)-phenylacetic acid, process for their preparation and their application as pharmaceutical preparations for topical use | HEUMANN PHARMA GMBH & CO (DE) | 1995-04-26 | — | — | EP | claimed |
| EP-0400558-B1 | Phenylacetic acid derivative | VINAS LAB (ES) | 1994-09-07 | — | — | EP | claimed |
| US-5254583-A | Antiinflammatory agents | HEUMANN PHARMA GMBH & CO. (DE) | 1993-10-19 | — | — | US | claimed |
| EP-0326637-B1 | NEW 2-ANILINOPHENYLACETIC ACID DERIVATIVE | Mikasa Seiyaku Co., Ltd. (JP) | 1992-09-23 | — | — | EP | claimed |
| EP-0400558-A2 | Phenylacetic acid derivative | LABORATORIOS VINAS S.A. (ES) | 1990-12-05 | — | — | EP | claimed |
| EP-0326637-A1 | New 2-anilinophenylacetic acid derivative | Mikasa Seiyaku Co., Ltd. (JP) | 1989-08-09 | — | — | EP | claimed |
| US-4734276-A | L-lysine pyruvate and l- histidine pyruvate and their use in therapy of tissue and mucosa damage | INSTITUT DR. ZIEGLER (CH) | 1988-03-29 | — | — | US | claimed |
| US-4309421-A | Stabilized parenterally administrable solutions | A. NATTERMANN & CIE. GMBH (DE) | 1982-01-05 | — | — | US | claimed |
| US-4256639-A | Process for the synthesis of isatin derivatives | AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO (IT) | 1981-03-17 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11389512-B2 | Use of low molecular weight fractions of human serum albumin in treating diseases | ALB, TSLP, IL2 | CXCL8 483/4885LMNA 4630/4885MEN1 4781/4885 |
| US-20230017266-A1 | Cyclooxygenase-2 Inhibition for the Treatment of SAA-high Asthma | PTGES2, SAAL1, PTGS2 | CXCL8 1064/4885LMNA 1342/4885MEN1 4125/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.